Aortic Stenosis

Treatment Guidelines

Aortic Stenosis

Treatment Guidelines

Aortic Stenosis Treatment Guidelines

“Surgical intervention should be performed promptly once even minor symptoms occur.”
–C.M. Otto, University of Washington School of Medicine, Seattle, Washington1

European Society of Cardiology AS Treatment Guidelines2

Treatment Guidelines

According to the ESC/EACTS Guidelines, severe AS is defined by the following echocardiographic characteristics:2

  • Aortic valve area: < 1 cm2
  • Indexed valve area < 0.6 cm2/m2 body surface area
  • Mean transvalvular pressure: > 40 mmHg
  • Velocity ratio: < 0.25
  • Jet velocity: > 4.0 m/sec

The 2012 ESC/EACTS guidelines for AS recommend replacement for Class I patients, i.e. those with severe AS and symptoms. TAVI is indicated in patients with severe symptomatic AS who are not suitable for AVR as assessed by a “heart team” and should be considered in high risk patients who may still be suitable for surgery, but in whom TAVI is favored by a “heart team” based on the individual risk profile.2 The 2008 ACC/AHA guidelines recommend that AVR should be performed in virtually all symptomatic patients with severe AS. Both guidelines stress that age is not a contraindication to surgery.2,3

Download Aortic Stenosis Brochure

References
  1. Otto CM. Timing of aortic valve surgery. Heart 2000;84:211-8.
  2. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012;33:2451-96.
  3. Bonow RO, Carabello BA, Chatterjee K, et al.; 2006 Writing Committee Members; American College of Cardiology/American Heart Association Task Force. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008;118:e523-661.

Any quotes used in this material are taken from independent third-party publications and are not intended to imply that such third party reviewed or endorsed any of the products of Edwards Lifesciences.

For Professional Use

For Professional Use

See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse event.

Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Please update your browser

Please update to a current version of your preferred browser, this site will perform effectively on the following:

Unable to update your browser?

If you are on a computer, that is maintained by an admin and you cannot install a new browser, ask your admin about it. If you can't change your browser because of compatibility issues, think about installing a second browser for browsing and keep this old one for compatibility